Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2026European Heart Journal - Cardiovascular PharmacotherapyOpen Access

Real-world study evaluates ARNI therapy for preventing AF in HFrEF against randomized benchmarks.

View Full Paper
Ask AI
Bookmark
Share

Key result

ARNI therapy was assessed for preventing atrial fibrillation in heart failure with reduced ejection fraction by comparing real-world evidence against randomized benchmarks.

Authors

EVEnrico VolpeSJStanislovas S. JankauskasPMPasquale Mone

Discussion

Loading...

Member takes

Overview

Evidence review examines atrial fibrillation prevention in heart failure with reduced ejection fraction, highlighting the role of ARNI across trials and clinical practice.

Key Points

  • Assess whether angiotensin receptor-neprilysin inhibitors (ARNI) prevent atrial fibrillation in heart failure with reduced ejection fraction by comparing real-world evidence with clinical trial benchmarks.
  • Evaluated clinical trial data and benchmark findings regarding sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
  • Synthesized observational and real-world evidence measuring incident and recurrent atrial fibrillation outcomes following ARNI initiation.
  • Real-world studies demonstrate an association between ARNI therapy and reduced rates of new-onset atrial fibrillation compared to conventional renin-angiotensin system inhibitors.
  • Trial benchmarks and mechanistic analyses indicate that ARNI reduces atrial stretch and electrical remodeling, contributing to lower arrhythmia burden.

Cite This Study

Volpe et al. (2026) studied this question. ARNI therapy was assessed for preventing atrial fibrillation in heart failure with reduced ejection fraction by comparing real-world evidence against randomized benchmarks.

synapsesocial.com/papers/6ab60edd406bf401c1467774https://doi.org/10.1093/ehjcvp/pvag080
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations2022 · 2 citations
  2. 2The Impact of Angiotensin Receptor–Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis2022 · 12 citations
  3. 3Impact of sacubitril/valsartan on atrial fibrillation burden in heart failure: a retrospective observational study2024
  4. 4Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction2022 · 15 citations
  5. 5Real-world utilisation of angiotensin-neprilysin inhibitors in older adults with heart failure2021 · 2 citations